A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
ConditionCOVID-19 Vaccines
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-64
SponsorBioNTech SE
About this trial
The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age.
This study is seeking participants who:
* are medically stable * have not had a recent COVID-19 infection * have not had a recent vaccination * do not have medical conditions that increase their risk of complications from COVID-19
All participants in this study will randomly receive 1 injection into their arm of either:
* BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or * Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough).
The study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines.
Participants will be in the study for about 12 months.
Eligibility criteria
Qualifiers
None
Disqualifiers
Participants who tested positive for COVID-19 within 6 months (180 days) prior to Visit 1
Participants who have recently received a vaccine, or plan to receive a nonstudy COVID-19 or comparator vaccine during participation.
Trial design
Treatments tested in this trial
- BNT162b2 Vaccine
- Tdap Vaccine
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
BioNTech SE
Lead sponsor
Pfizer
Collaborator
Source ClinicalTrials.gov